5. All endpoints in comparison 2.

Endpoint	No. events/patients	HR (95% CI), p	Heterogeneity p
Survival	368/872	0.65 (0.53‐0.80), 0.00004	0.06
Disease‐free survival	414/872	0.68 (0.56‐0.82), 0.0001	0.02
Loco‐regional disease‐free survival	402/872	0.68 (0.56‐0.82), 0.0001	0.005
Metastases‐free survival	381/872	0.63 (0.52‐0.78), 0.00001	0.217